-
-
-
-
-
-
-
Medincell launches private placement for 6% of share capital
-
-
-
-
-
-
-
Medincell Launches a Global Offering for Approximately 10% of Its Share Capital
-
-
-
-
-
-
-
Teva and MedinCell Announce FDA Approval of UZEDY™ (risperidone) Extended-Release Injectable Suspension, a Long-Acting Subcutaneous Atypical Antipsychotic Injection, for the Treatment of Schizophren
-
-
-
-
-
-
-
MedinCell Announces Fiscal Year Consolidated Results
-
-
1,158,059 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

